Paperonium

Cancer treatment · BMC Med · 2026

Summary: no severe side effects from the treatment. The paper’s own results: two, one fatal.

The summarynoneThe paper’s own table and results2 of 87; one died012
The summarynoneThe paper’s own table and results2 of 87; one died012

Patients, of 87, with severe side effects rated as caused by the treatment

The paper says

A modified herpes virus, injected into tumors, had its first test in people with advanced cancer. For the 87 patients in the study’s main part, the paper’s opening summary reports no severe side effects from the treatment and calls its safety “favorable”.

Its own data show

The paper’s own table counts 2 of 87 patients with severe side effects it rates as caused by the treatment. Its results name them: a head and neck cancer patient who died after severe breathing difficulty, and a sarcoma patient with severe anemia (too few red blood cells).

A first test in people is mainly a test of safety. Later the paper contradicts itself, saying none of the 6 deaths it lists, one from breathing difficulty, was caused by the treatment. Either way, the anemia case alone makes the summary’s “none” wrong. The death was in head and neck cancer, where the paper says the treatment looked best.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC · BMC Med (2026) · doi:10.1186/s12916-026-04695-1